CGEN Key Statistics, Chart & Performance
The current stock price of CGEN is 1.88 USD. In the past month the price increased by 15.34%. In the past year, price increased by 14.63%.
CGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About CGEN
Company Profile
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Company Info
COMPUGEN LTD
Azrieli Center, 26 Harokmim St., Bldg D
Holon 5885849 IL
CEO: Anat Cohen-Dayag
Employees: 74
Phone: 97237658585
COMPUGEN LTD / CGEN FAQ
What does CGEN do?
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
What is the current price of CGEN stock?
The current stock price of CGEN is 1.88 USD. The price increased by 14.63% in the last trading session.
Does CGEN stock pay dividends?
CGEN does not pay a dividend.
What is the ChartMill rating of COMPUGEN LTD stock?
CGEN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for CGEN stock?
COMPUGEN LTD (CGEN) currently has 74 employees.
Who owns COMPUGEN LTD?
You can find the ownership structure of COMPUGEN LTD (CGEN) on the Ownership tab.
What is the outstanding short interest for COMPUGEN LTD?
The outstanding short interest for COMPUGEN LTD (CGEN) is 1.03% of its float.
CGEN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CGEN. When comparing the yearly performance of all stocks, CGEN turns out to be only a medium performer in the overall market: it outperformed 56.81% of all stocks.
CGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGEN. The financial health of CGEN is average, but there are quite some concerns on its profitability.
CGEN Financial Highlights
Over the last trailing twelve months CGEN reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS decreased by -1600% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.17% | ||
| ROE | -38.52% | ||
| Debt/Equity | 0 |
CGEN Forecast & Estimates
10 analysts have analysed CGEN and the average price target is 6.38 USD. This implies a price increase of 239.1% is expected in the next year compared to the current price of 1.88.
For the next year, analysts expect an EPS growth of -96.03% and a revenue growth -84.63% for CGEN